Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Deyuan Pharmaceutical (920735) had a net sell of 4.4531 million yuan by main funds on March 11.
Securities Star News: As of the close on March 11, 2026, Deyuan Pharmaceutical (920735) closed at 34.65 yuan, down 0.43%. The turnover rate was 1.59%, with a trading volume of 16,500 lots and a transaction amount of 57.0481 million yuan.
Regarding capital flow data on March 11, main funds net outflow was 4.4531 million yuan, accounting for 7.81% of the total transaction amount. Hot money net inflow was 13,600 yuan, accounting for 0.02%. Retail investor net outflow was 389,100 yuan, accounting for 0.68%.
Deyuan Pharmaceutical’s 2025 annual report shows that the company’s main business revenue was 1.058 billion yuan, an increase of 21.8% year-on-year; net profit attributable to the parent was 237 million yuan, up 33.87%; net profit after deducting non-recurring gains and losses was 229 million yuan, up 34.79%. In Q4 2025, the company’s quarterly main business revenue was 262 million yuan, up 21.53% year-on-year; quarterly net profit attributable to the parent was 78.0027 million yuan, up 26.42%; quarterly net profit after deducting non-recurring gains and losses was 74.2119 million yuan, up 21.51%. The debt ratio was 16.82%, investment income was 8.2693 million yuan, financial expenses were -562,000 yuan, and gross profit margin was 84.08%. Deyuan Pharmaceutical (920735) main business: research, development, production, and sales of chemical drug preparations.
Capital flow explanation: Refers to inferring capital flow direction through price changes. When the stock price is rising, the transaction volume generated by active buy orders is the driving force behind the stock price increase, which is defined as capital inflow. When the stock price is falling, the transaction volume generated by active sell orders is the driving force behind the decline, which is defined as capital outflow. The difference between the two on the same day is the net force remaining after offsetting the two forces, driving the stock price up. The main fund flow, hot money flow, and retail investor flow are calculated based on transaction amounts of individual trades.
Note: Main funds refer to large orders, hot money refers to very large orders, and retail investors refer to medium and small orders.
The above content is compiled by Securities Star from publicly available information, generated by AI algorithms (Wangxin Calculation Backup 310104345710301240019), and does not constitute investment advice.